We present a case of a 47-year-old, nulliparous woman who underwent a maximal debulking surgery and adjuvant chemotherapy with Taxolecarboplatin for ovarian malignancy, and subsequently had a secondary laparotomic debulking surgery 8 months later due to tumor recurrence. However, after this surgery, the patient refused to take subsequent chemotherapy due to its discomforts. Her wound healing was optimum; however, a small mass developed over the scar and was felt 6 months after the last surgery and it progressed since then to 4 cm Â 5 cm in size. The mass is irregular in contour, with erosion and bleeding over the previous laparotomy scar below the umbilicus.
to the skin presenting as nodular lesions, commonly on the abdomen or thorax and particularly on abdominal wall incisions, either laparotomy or laparoscopy scars. He also concluded that there is poor prognosis for ovarian cancers with skin metastasis with a survival rate ranging between 2 months and 65 months. 2 V. Manvelyan et al (2016) in their article review, points out that in the development of port-site (scar) metastases, the major role is played by biologically aggressive diseases, tumor manipulation, wound contamination, and surgery-related factors. 3 Thus in conclusion, the skin metastasis in ovarian cancer is seen not only in laparoscopic port sites but can occur also in laparotomy scars. 
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